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Summary
 
Antigen injection into animals causes antigen-specific T cells to become activated and, rapidly
thereafter, die. This antigen-induced death is inhibited by inflammation. To find out how in-
flammation has this effect, various cytokines were tested for their ability to interfere with the
rapid death of activated T cells. T cells were activated in vivo, isolated, and cultured with the
test reagents. Two groups of cytokines were active, members of the interleukin 2 family and
the interferons (IFNs) 
 
a
 
 and 
 
b
 
. This activity of IFN-
 
a
 
/
 
b
 
 has not been described previously. It
was due to direct effects of the IFNs on the T cells and was not mediated by induction of a sec-
ond cytokine such as interleukin 15. IFN-
 
g
 
 did not slow the death of activated T cells, and
therefore the activity of IFN-
 
a
 
/
 
b
 
 was not mediated only by activation of Stat 1, a protein that
is affected by both classes of IFN. IFN-
 
a
 
/
 
b
 
 did not raise the levels of Bcl-2 or Bcl-
 
XL
 
 in T cells.
Therefore, their activity was distinct from that of members of the interleukin 2 family or CD28
engagement. Since IFN-
 
a
 
/
 
b
 
 are very efficiently generated in response to viral and bacterial in-
fections, these molecules may be among the signals that the immune system uses to prevent ac-
tivated T cell death during infections.
Key words: interferon 
 
g
 
 • apoptosis • interferon type I • cell survival • T cell
 
I
 
njection of antigen or superantigen into animals activates
specific T cells and allows them to go through several
rounds of division. However, these activated cells rapidly go
on to die (1–4). Activation-induced death is caused by sev-
eral processes in vivo. These probably include engagement
of Fas and TNF receptors on the surfaces of activated T cells
by their ligands, lack of essential growth factors such as IL-2
or -4 (5–8), and also other unknown phenomena.
Whatever the causes of activated T cell death, clearly this
phenomenon is not compatible with a productive immune
response since because of it animals frequently contain
fewer antigen-specific T cells several days after exposure to
the antigen than they did before antigen was given. How-
ever, it is now known that activation-induced death is in-
hibited in animals if they are given antigen and an agent
that stimulates inflammation. For example, we have shown
that superantigen-specific T cells survive better if superanti-
gen-immunized animals are also exposed to bacterial LPS,
TNF-
 
a
 
, or vaccinia virus (9, 10, and Mitchell, T., J. Kap-
pler, and P. Marrack, manuscript submitted for publica-
tion). Others have shown that antigen-specific T cells can
be rescued by similar agents (4, 11).
In attempts to find out what makes activated T cells die
or live in animals, we have developed an in vitro system in
which the behavior of the T cells in tissue culture reflects
their fate in vivo. In this system T cells are activated in
animals with antigen or superantigen in the presence or ab-
sence of an inflammatory agent. 2 d later the T cells are pu-
rified and placed in culture. T cells that have been activated
in animals by exposure to antigens and inflammatory agents
die slowly in culture. T cells activated in animals by antigen
alone and which therefore are destined to die in animals
also die rapidly in culture. We and others have previously
shown that members of the IL-2 family of cytokines pre-
vent this rapid death via a pathway that probably involves
Bcl-2 induction (12–14). In an attempt to find other factors
that may interfere with activated T cell death, we screened
a large number of other cytokines. Of these only one fam-
ily, the type I IFNs (IFN-
 
a
 
/
 
b
 
) were effective. Experiments
with cells from IFN-
 
a
 
/
 
b
 
R–deficient mice showed that, in
vitro, the IFN-
 
a
 
/
 
b
 
 acted directly on the T cells and not, as
has been described in vivo (15), via intermediary induction
of IL-15. The IFN-
 
a
 
/
 
b
 
 did not act by raising levels of
Bcl-2 or Bcl-
 
XL
 
 in the activated cells. We conclude that IFN-
 
a
 
/
 
b
 
 can act as survival factors for activated T cells, and that
they act via an intracellular pathway that is not shared by
IFN-
 
g
 
 and its receptor and is not the same as that induced
by the IL-2 family or CD28 engagement (12–14, 16–24). 
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Materials and Methods
 
Mice.
 
C57BL/10SgSnJ (B10) mice were purchased from The
Jackson Laboratory. 129/SvEv animals came from Taconic Farms
and IFN-
 
a
 
/
 
b
 
R–deficient mice (25) were bred from pairs of mice
provided by Drs. R. Schreiber (Washington University, St. Louis,
MO) and M. Aguet (Institute of Experimental Immunology, Zur-
ich, Switzerland). All animals were kept under specific pathogen-
free conditions in the Biological Resource Center at the National
Jewish Medical and Research Center.
 
Mouse Manipulations.
 
T cells were activated in mice by injec-
tion of the superantigen staphylococcal enterotoxin B (SEB;
Toxin Technology).
 
1
 
 Mice were given 150 
 
m
 
g SEB intrave-
nously in balanced salt solution.
 
Cell Purification and Staining.
 
T cells were purified on nylon
wool columns (26). Intact cells were stained as previously de-
scribed (27) in balanced salt solution, 2% FBS, 0.1% sodium azide
(staining buffer) with biotinylated anti-V
 
b
 
3, 6, 8.1–3, or 17. The
biotinylated antibodies were detected with streptavidin coupled
to PE or cychrome (Cy). Cells were also stained with FITC or
Cy-coupled anti–mouse CD4 or anti–mouse CD8 and PE-cou-
pled antibody to the MHC class I protein, K
 
b
 
.
Cells were analyzed for expression of Bcl-2 as previously de-
scribed (17). In brief, intact cells were stained as described above
with anti-V
 
b
 
 and/or anti-CD4 and/or anti-CD8 antibodies. The
cells were then permeabilized in staining buffer containing 0.03%
saponin and hamster anti–mouse Bcl-2. The mixture was incu-
bated at room temperature for 30 min. The cells were then
washed twice with staining buffer, 0.03% saponin before addition
of FITC-coupled mouse anti–hamster immunoglobulin antibod-
ies. Controls included cells stained without addition of anti–Bcl-2
or stained with anti–human Bcl-2.
Intracellular Bcl-X was analyzed by a method similar to that
used for Bcl-2. Intact cells were stained as described above,
washed, permeabilized with 0.1% saponin, and incubated with
rabbit anti–mouse Bcl-X antibodies (Transduction Labs.) at room
temperature for 30 min. The cells were washed again and incu-
bated for an additional 30 min at room temperature with FITC–
coupled goat anti–rabbit immunoglobulin (Fisher Scientific Co.)
before final washing and analysis.
In some experiments T cells from IFN-
 
a
 
/
 
b
 
R–deficient mice
were labeled with carboxyfluorescein diacetate succinimidyl ester
(CFSE; Molecular Probes Inc.) (28) by incubation for 15 min at
room temperature in balanced salt solution concentrations of 10
 
7
 
cells/ml and 0.1 
 
m
 
g/ml CFSE.
In most of the experiments in this paper, dead cells were dis-
tinguished from live by their characteristics on the forward versus
side scatter bit maps from the cytofluorographs. This method of
distinguishing live from dead lymphocytes was in agreement with
analyses in which dead cells were identified by their possession of
 
,
 
2 N amounts of DNA (see Fig. 1), by their ability to take up
propidium iodide or to bind annexin V (Teague, K., D. Hilde-
man, and T. Mitchell, unpublished results).
Except where otherwise mentioned, all reagents were prepared
in our laboratory or purchased from PharMingen. Staining was
read on FACScan
 
®
 
 or FACScalibur
 
®
 
 instruments (Becton Dickin-
son) and analyzed using Cell Quest software (Becton Dickinson).
 
Cell Culture and Reagents.
 
Purified T cells were cultured as
previously described (9, 14) in the presence or absence of cyto-
kines. Mouse IL-2 and human IL-15 were purchased from R&D
 
Systems. A mixture of mouse IFN-
 
a
 
/
 
b
 
 was bought from Sigma
Chemical Co. Recombinant mouse IFN-
 
a
 
 and -
 
b
 
 were obtained
from CalBiochem. The IFN preparations all contained 
 
,
 
10 ng
LPS/10
 
5
 
 U IFN.
 
Analysis of Cell Division.
 
Lymphocyte proliferation in culture
was assayed by uptake of [
 
3
 
H]TdR. In brief, cells were cultured at a
starting concentration of 3 
 
3
 
 10
 
5
 
 cells/150 
 
m
 
l in the wells of
96-well tissue culture plates. 2–3 d later, 1 
 
m
 
Ci [
 
3
 
H]TdR was
added to each well and the cells were incubated for an additional 6 h
before harvest using a 1450 Microbeta Plus liquid scintillation
counter (Wallac). Cell division was also analyzed after permeabili-
zation of the cells in 0.3% saponin and addition of 5 
 
m
 
g/ml propid-
ium iodide. The percentages of cells in G1 and G2/S, and with
 
,
 
2 N amounts of DNA were then identified cytofluorographically.
 
Results
 
IFN-
 
a
 
/
 
b
 
 Improve the Survival of Activated T Cells.
 
T cells
that have been activated in animals die rapidly in vivo or in
culture unless their activation occurred in the presence of
an inflammatory agent such as LPS or an adjuvant (1–4, 9,
10). To find out how inflammation has this effect, we
screened a large number of agents for their ability to pre-
vent the death of T cells activated in vivo and then cul-
tured in vitro (Table I). Many of the agents had no effect in
this assay. Members of two cytokine families, the IL-2 fam-
ily and the type I IFN (IFN-
 
a
 
/
 
b
 
) family, were active. Sev-
eral groups including ourselves have previously described
the effects of IL-2 family members (12–14, 29, 30); how-
ever, the ability of IFN-
 
a
 
/
 
b
 
 to prevent activated T cell
death has not been reported previously.
An example of an IFN-
 
a
 
/
 
b
 
 experiment is shown in Fig. 1.
T cells were activated in vivo by injection of SEB, a super-
 
1
 
Abbreviations used in this paper:
 
 CFSE, carboxyfluorescein diacetate suc-
cinimidyl ester; CY, cychrome; SEB, staphylococcal enterotoxin B.
 
Table I.
 
Agents Tested for Their Effects on the Survival of 
Activated T Cells In Vitro
 
Agents that have no effect Agents that increase survival
IL-1
 
b
 
IL-8 IL-2
IL-6 RANTES IFN-
 
a
 
IL-12 MIP-1
 
a
 
IL-4
IFN-
 
g
 
MIP-1
 
b
 
IFN-
 
b
 
TNF-
 
a
 
MIP-2 IL-7
TNF-
 
b
 
VEGF IL-15
IL-3 PEGF
IL-5 TGF-
 
b
 
IL-10 CD28 engagement
IL-9 LPS
IL-13 Platelet-activating factor
Thrombopoietin
Agents were tested at concentrations recommended by the manufac-
turers or obtained from the literature. 
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antigen which reacts with T cells bearing members of the
V
 
b
 
8 family in their TCRs, into mice. 2 d later lymph node
T cells were purified and cultured in the presence or ab-
sence of IFN-
 
a
 
/
 
b
 
. 1 d later, the percentages of live V
 
b
 
8
 
1
 
or control V
 
b
 
6
 
1
 
 T cells were measured using either live/
dead gates of the forward versus side scatter bit maps of the
cells or DNA content, as assessed by staining of permeabi-
lized cells with propidium iodide.
The results of both types of assays for dead cells were sim-
ilar, except that in every case fewer of the cells were alive
after culture as defined by forward versus side scatter than as
defined by DNA content (Fig. 1). This difference was prob-
ably due to the fact that DNA degradation is a relatively late
event in apoptosis (31–33). Because measurement of cell
survival by light scatter properties allowed more flexible use
of staining reagents and identified dead cells at an earlier
stage, this assay was used to define dead cells in the remain-
ing experiments described in this paper. However, in most
cases the results were confirmed using DNA content or cell
permeability as measures of cell survival.
Fig. 1 shows that 
 
,
 
40% of the control V
 
b
 
6
 
1
 
 cells died
during overnight culture. In contrast, almost 70% of the
SEB-activated, V
 
b
 
8
 
1
 
 T cells died. Thus, as we have previ-
ously described, T cells die more quickly in culture if they
have previously been activated in vivo (9). Culture with
IFN-
 
a
 
/
 
b
 
 slightly increased the survival of the resting,
V
 
b
 
6
 
1
 
 T cells in overnight culture, but dramatically pre-
vented the death of the activated, V
 
b
 
8
 
1
 
 T cells (Fig. 1).
The fact that IFN-
 
a
 
/
 
b
 
 have only a very slight effect on
the rate of death of resting T cells was also demonstrated in
an experiment in which IFN-
 
a
 
/
 
b
 
 was titrated. Increasing
doses of IFN-
 
a/b had increasing abilities to promote the
survival of activated T cells and had very little effect on the
survival of resting T cells (Fig. 2). This was not due to ab-
sence of IFN-a/b receptors on resting T cells, since, as
shown in Fig. 3, culture in IFN-a/b increased the levels of
class I MHC on resting T cells. For CD41 T cells, the ef-
fects of IFN-a/b on class I expression were less dramatic if
the T cells were resting compared with if they were acti-
vated. On the other hand, for CD81 T cells the dose–
response curve was almost exactly the same whether or not
the cells were activated.
IFN-a/b increased the survival of both CD41 and
CD81 T cells, providing the cells were activated. Thus, as
Figure 1. IFN-a/b prevent the death of
activated T cells. T cells were isolated from
the lymph nodes of mice given 150 mg SEB
2 d previously. The cells were cultured for
24 h in the absence or presence of 3,333 U/ml
IFN-a/b. The cells were then stained with
FL-anti-CD4, biotinylated anti-Vb8x, or
anti-Vb6 followed by PE-labeled streptavidin
and Cy-labeled anti-CD8. These cells were
then identified as live or dead based on their
light scatter properties (top). Separate wells
of cells cultured under identical conditions
were stained with FL-anti-Vb6 or anti-Vb8.
These cells were then permeabilized with sa-
ponin and incubated with propidium iodide
to measure their DNA content. Light scatter
gates were set for the permeabilized cells
and propidium iodide staining was assessed
as shown (bottom). Results shown are typi-
cal of duplicate cultures. Values shown on
the figure are the percentage of the indi-
cated cells that were alive as defined by the
method used.
Figure 2. IFN-a/b prevent the death of activated T cells. IFN-g does
not. T cells were isolated from the lymph nodes of control B10 mice, or
from B10 mice that had been injected with 150 mg SEB 2 d previously.
The cells were cultured for 20 h in the presence of the indicated concen-
trations of IFN-a/b or IFN-g. The percentages of live Vb81 or Vb82
cells in the cultures were determined by flow cytometry as described in
the legend to Fig. 1, using light scatter properties as an indicator of sur-
vival. Results shown are the mean 6SE of triplicate cultures.524 Type I Interferons Keep Activated T Cells Alive
shown in Fig. 2, increasing doses of IFN-a/b kept increas-
ing percentages of CD4 or CD81 SEB-activated, Vb81 T
cells alive. However, the effects of IFN-a/b on cell sur-
vival were consistently more pronounced for CD81 T cells
than for CD41 T cells. This was not because CD41-acti-
vated T cells are intrinisically less sensitive to IFN-a/b
than are CD81-activated cells since, as shown in Fig. 3,
culture in increasing concentrations of IFN-a/b raised class
I MHC expression on both CD41- and CD81-activated T
cells. In fact, class I was induced to higher levels on acti-
vated CD41 cells than on CD81 cells.
The extent to which activated T cells died, and therefore
to which IFN-a/b rescued them, varied with time in cul-
ture and strain of mice. For example, the cultures shown in
Fig. 2 were incubated for 20 h and those shown in Fig. 4
were incubated for 24 h, and there was more extensive
death in the absence of, and proportional rescue in the
presence of, IFN-a/b in the latter experiments than in the
former. The mouse strain from which the activated T cells
were derived also affected rates of death in vitro. Thus, the
activated T cells from 129 mice (Table II) died more slowly
than those from C57Bl/10 mice, a difference between 129
and C57Bl/10 T cells that we have consistently observed in
many experiments.
IFN-b is distinguished from the large family of IFN-a’s
by sequence differences. However, both IFN-a and IFN-b
are thought to act via the same heterodimeric receptor
(IFN-a/bR; references 34, 35). Since both IFN-a and
IFN-b act on the same receptor, we expected that each
type of protein would have the same effect on T cells as the
mixture of the two that was used for the experiments
shown thus far in this paper. To find out whether this was
so, T cells were activated in vivo with SEB, harvested and
purified 2 d later, and cultured in various concentrations of
IFN-a or IFN-b. As shown in Fig. 4, both kinds of IFN
increased the life expectancy of activated T cells in vitro;
however, IFN-b was somewhat more active than the
IFN-a protein tested. Whether this represents a consistent
difference between IFN-b and all the members of the
IFN-a family awaits further investigation.
In summary, these experiments show that IFN-a and
IFN-b promote the survival of activated T cells in vitro.
IFN-a/b has little or no effect on the survival of resting T
cells, despite the fact that these cells can respond to IFN-a/b
by raising their surface levels of class I strongly on CD81 T
cells and to a lesser extent on CD41 cells.
Figure 3. Activated and resting T cells bear receptors for IFN-a/b and
IFN-g. Mice were primed and T cells were cultured as described in the
legend to Fig. 2. 20 h after the start of culture, the cells were isolated and
stained for Vb8, Kb, and CD4 or CD8 as described in Materials and Meth-
ods. The results shown are the mean 6 SE of triplicate cultures of staining
with anti-Kb antibody in arbitrary units based on staining intensities.
Figure 4. Both IFN-a and IFN-b affect the survival of activated T
cells. T cells were activated and purified as described in the legend to Fig.
1. The cells were cultured for 24 h in the presence of various concentra-
tions of IFN-a or IFN-b and the percentages of live activated (Vb81) T
cells were determined by flow cytometry. Results shown are the mean 6
SE of triplicate cultures.
Table II. IFN-a/b Act Directly on T Cells
Additions
to culture
Percentage indicated of cells
surviving in mixed cultures
Wild-type IFNR-a/b–deficient
CD4 CD8 CD4 CD8
None 43.6 6 1.8 33.5 6 0.4 45.9 6 2.4 21.5 6 0.9
IFN-a/b 49.7 6 0.6 54.4 6 0.8 43.9 6 0.4 22.4 6 0.6
IFN-a/bR–deficient mice and mice of their closely related wild-type
strain, 129/SvEv, were injected intravenously with 150 mg SEB. 2 d
later T cells were isolated from the lymph nodes of the mice. The cells
from the IFN-a/bR–deficient mice were staIned with CFSE as de-
scribed in Materials and Methods. Mixtures containing equal numbers
of cells from each type of mouse were cultured for 28 h in the absence
or presence of 3,333 U/ml IFN-a/b and then stained with PE–labeled
anti-CD4 or anti-CD8 and biotinylated anti-Vb8 followed by CySA.
Results shown are the mean 6 SE of data from three identical cultures.525 Marrack et al.
IFN-a/b Act Directly on Activated T Cells and Do Not
Stimulate T Cell Proliferation. Tough et al. recently re-
ported that IFN-a/b make CD44hi CD81 T cells divide in
vivo (36). Subsequently this group showed that the IFNs
probably do not act directly, but rather indirectly by induc-
tion of IL-15, which in turn affects the T cells (15). To find
out whether IFN-a/b were acting in a similarly indirect
manner in vitro, we set up cultures containing mixtures
of SEB-activated T cells from normal and IFN-a/bR–defi-
cient mice. The normal T cells were distinguished from the
IFN-a/bR–deficient cells by labeling the latter with CFSE.
IFN-a/b increased the survival of the T cells from normal
mice but had no effect on T cells lacking IFN-a/bRs (Table
II), even though the two types of cells were cultured to-
gether. Toxicity due to CFSE labeling did not contribute
to this since identical results were obtained in mixed cul-
tures in which the normal T cells were labeled with CFSE
and the IFN-a/bR cells were unlabeled. Thus, IFN-a/b
were acting directly on T cells in culture. Of course under
some circumstances they may also act indirectly via induc-
tion of cytokines such as IL-15, but these effects were not
manifest in our cultures of purified T cells.
IL-15 stimulates the proliferation of activated T cells but
IFN-a/b do not (37–40). To confirm the idea that, in the
experiments described in this paper, IFN-a/b were not
acting via IL-15, we tested their effects on T cell prolifera-
tion. T cells were isolated from mice given SEB 2 d previ-
ously and cultured in the presence of different concentra-
tions of IFN-a/b or as controls without added cytokines
or with IL-2. The cells cultured alone did not proliferate.
They divided vigorously in response to IL-2. Such cells also
divided in response to IL-15 (data not shown). The cells
did not divide at all in response to IFN-a/b (Fig. 5). The
same conclusion was drawn from experiments in which T
cells were labeled with CFSE and cultured in the presence
or absence of IFN-a/b or IL-15. After 24 h, CFSE staining
showed that, of the activated CD81 T cells that were still
alive, 8.9 6 1.2% had divided if the cells were cultured
alone, whereas 5.5 6 0.6 or 15.5 6 0.74% had divided if
the cells were cultured in IFN-a/b or IL-15, respectively.
Likewise, counts of total cell yield showed that there was
no difference in the number of T cells per culture after 24 h
of incubation in the presence or absence of IFN-a/b. In
one experiment, 6.1 6 0.5 3 105 cells were recovered
from cultures incubated for 24 h without IFN-a/b, and
5.4 6 0.3 3 105 cells were recovered from cultures incu-
bated with 3,333 U/ml IFN-a/b. Hence, IFN-a/b do not
cause activated T cells to divide.
These results showed that IFN-a/b were not acting via
induction of IL-15, since they did not stimulate activated T
cell division. Also, IFN-a/b did not cause a higher per-
centage of activated T cells to survive culture because they
stimulated T cells to proliferate and hence overgrow dying
cells. Rather, IFN-a/b promoted the survival of previ-
ously activated T cells.
IFN-g Has No Effect on the Survival of Activated T Cells.
IFN-a/b share many biological effects with IFN-g, even
though the two types of IFN act via different receptors (33,
34, 40). However, IFN-g did not prevent the deaths of ac-
tivated T cells. Thus, as shown in Fig. 2, incubation with
various concentrations of IFN-g had no effect on the sur-
vival of CD41 or CD81 activated or resting T cells. This
was not because these cells did not bear receptors for IFN-g
since, as shown in Fig. 3, incubation with IFN-g did raise
class I MHC levels on these T cells, albeit with a bell-
shaped dose–response curve.
It was surprising that IFN-g did not have the same activity
as IFN-a/b. Although the two types of IFNs act through
different receptors (34, 35, 41), they share many intracellular
signaling pathways and therefore have many similar effects
on cells (42, 43). The fact that the two types of IFNs differ in
this assay shows that IFN-a/b prevents T cell death via an
intracellular pathway that is not triggered by the IFN-g re-
ceptor. Therefore, although Stat1 activation may be required
for the effects described here (42), it is not sufficient.
The Protective Effects of IFN-a/b Were Not Mediated by In-
creased Bcl-2 or Bcl-X Levels. Other cytokines, including
IL-15, that protect activated T cells against death raise the
amounts of Bcl-2 in the activated cells (12, 14, 29). If
IFN-a/b were acting via IL-15, or by a route similar to
that induced by IL-2 family members, then they should
also raise Bcl-2 in the T cells. To check this, T cells were
isolated from mice primed 2 d previously with SEB and
stained for Bcl-2 content. At the time of isolation the acti-
vated, Vb81 T cells contained about half of the amount of
Bcl-2/cell that resting, Vb61 T cells did (footnote to Table
III). This lowered level of Bcl2 may contribute to the in-
creased rate of death of the activated cells.
The cells were then cultured in the presence or absence
of IFN-a/b or IL-2 or IL-15. As shown in Table III, all
three of these cytokines increased the survival rate of the
activated T cells. The effects of IL-2 and IL-15 were more
profound than those of IFN-a/b.
Figure 5. IFN-a/b do not stimulate the proliferation of activated T
cells. Lymph node T cells were purified from B10 mice primed 2 d previ-
ously with 150 mg/mouse SEB. The cells were cultured for 3 d in the
presence of the indicated concentrations of IFN-a/b or IL-2 and then
pulsed with [3H]TdR as described in Materials and Methods Results
shown are the mean 6 geometric SE of triplicate cultures. Similar results
were obtained from cells tested after 2 d of culture.526 Type I Interferons Keep Activated T Cells Alive
T cells cultured alone contained less Bcl-2 per cell after
culture than before. Activated, Vb81 T cells cultured
alone continued to contain less Bcl-2 per cell than resting,
Vb61 T cells did. This was also true for activated Vb81 T
cells cultured in IFN-a/b, even though these cells had a
markedly improved survival rate over that of activated cells
cultured alone. The amounts of Bcl-2 in the activated
Vb81 T cells did not fall so much or were maintained by
culture in IL-2 or IL-15.
As we have previously described, the high concentra-
tions of IL-2 or IL-15 used in this experiment also in-
creased the survival rate of the resting T cells (Table III,
reference 14, and data not shown). Commensurate with
this, the IL-2 family members helped to maintain Bcl-2
levels to a very small extent in CD41 T cells and much
more markedly in the CD81 T cells.
Bcl-X can also promote the survival of T cells (12, 13,
20, 24). Therefore we tested the effects of culture with
IFN-a/b on Bcl-X levels. Vb81 T cells were activated in
vivo using SEB and isolated 2 d later as described above. At
the time they were removed from the animals, the acti-
vated, Vb81 T cells contained z50% more Bcl-X per cell
than did the resting T cells (footnote to Table IV). This
was probably due to induction of Bcl-X in the activated
cells by CD28/B7 engagement (12, 13, 20, 24). After 1 d
in culture, the levels of Bcl-X in the activated, Vb81 and
resting, Vb61 T cells were the same. These levels were un-
affected by culture in IL-2, raised slightly (especially in the
CD81 T cells) by culture in IL-15, and completely unaf-
fected by culture in IFN-a/b (Table IV). Although these
results do not distinguish between the two forms of Bcl-X,
Bcl-XL and Bcl-XS, they do suggest that levels of either form
are not affected by IFN-a/b.
These results demonstrate that the rescuing activity of
IFN-a/b does not depend upon induction of either Bcl-2
or Bcl-X in activated T cells. Thus, the means whereby
Table III. IFN-a/b Do Not Raise Bcl-2 Levels in Activated T Cells
Culture
conditions
Percentage of Vb81 cells alive
Bcl-2 levels in
Vb81 cells with Vb61 cells with
CD4 CD8 CD4 CD8 CD4 CD8
No Addition 33.5 6 0.4 11.9 6 0.3 9.1 6 2.1 8.2 6 1.2 13.0 6 1.6 20.6 6 2.5
IFN-a/b 48.0 6 2.3 48.9 6 1.0 7.1 6 1.3 7.9 6 1.4 13.3 6 1.6 24.7 6 1.3
IL-2 73.3 6 4.3 73.3 6 4.2 18.1 6 2.1 36.5 6 1.5 15.0 6 1.5 39.0 6 2.7
IL-15 80.7 6 2.2 63.9 6 2.7 23.8 6 3.7 37.8 6 3.2 18.9 6 2.8 49.9 6 8.5
Lymph node T cells were purified from C57BL/10 mice given SEB 2 d previously. At that time, levels of Bcl-2 were 17.8 6 0.6 and 17.6 6 0.9 in
Vb8 cells bearing CD4 and CD8, respectively, and 28.2 6 0.9 and 38.7 6 0.9 in Vb6 cells bearing CD4 and CD8, respectively. Cells were cultured
for 24 h alone or with 3,333 U/ml IFN-a/b or 100 ng/ml IL-2 or 100 ng/ml IL-15 and then assayed for intracellular amounts of Bcl-2 as described
in Materials and Methods. Results shown are the mean 6 SE of staining with anti–Bcl-2 antibody in arbitrary units based on staining intensities of
three identical cultures minus the background without primary antibody.
Table IV. IFN-a/b Do Not Raise Bcl-X Levels in Activated T Cells
Culture conditions
Bcl-X levels in
Vb81 cells bearing Vb61 cells bearing
CD4 CD8 CD4 CD8
No addition 23.0 6 2.2 29.0 6 1.7 21.6 6 2.5 32.0 6 5.5
IFN-a/b 25.2 6 2.9 27.7 6 4.4 22.1 24.1 6 3.7
IL-2 25.7 6 2.8 28.3 6 0.5 20.3 6 2.8 25.7 6 2.3
IL-15 30.3 6 1.0 46.2 6 6.1 23.2 6 4.4 46.5 6 4.0
Lymph node T cells were purified from C57BL/10 mice given SEB 2 d previously. At that time Bcl-X levels were 51.3 6 1.9 and 49.9 6 1.9 in
Vb81 cells bearing CD4 and CD8, respectively, and 35.5 6 0.9 and 37.9 6 1.3 in Vb61 cells bearing CD4 and CD8, respectively. Cells were cul-
tured for 24 h alone or with 3,333 U/ml IFN-a/b or 100 ng/ml IL-2 or IL-15 and then assayed for intracellular amounts of Bcl-X as described in
Materials and Methods. Results shown are the mean 6 SE of three identical cultures in arbitrary units of Bcl-X based on staining intensities minus the
background without primary antibody. Cell survival rates were as listed in Table III.527 Marrack et al.
IFN-a/b protect activated T cells against death must be
different than those used in protection by IL-2 family
members or by CD28 engagement.
Discussion
Experiments described elsewhere show that T cells that
have been activated in vivo in the absence of adjuvant die
rapidly in animals or after isolation and culture (1–4, 9–12).
In vitro, a number of cytokines prevent the deaths of these
activated cells. Previously, we and others have shown that
members of the IL-2 family do this very effectively (12–14,
29). In this paper we show that IFN-a/b are also active.
The IL-2 family and IFN-a/b do not act in the same
way. IL-2 and its relatives all have the ability to induce Bcl-2
synthesis in responsive T cells (12–14, 29). It is likely that it
is this increase in Bcl-2 which increases the life expectancy
of the cells. Members of the IL-2 family also have, to vary-
ing degrees, the ability to induce proliferation of the re-
sponding T cells. IL-2 and IL-15 are particularly effective
in this regard, and IL-4 and IL-7 are less so (14). On the
other hand, the IFN-a/b family does not act in any of
these ways. IFN-a/b do not increase Bcl-2 levels in T
cells. IFN-a/b also do not stimulate T cell division. In fact,
IFN-a/b are often thought to be inhibitors rather than
stimulators of proliferation (38–40).
Recently, Tough et al. have studied the effects of IFN-
a/b on T cells. They showed that induction of IFN-a/b
in animals caused a subset of what appear to be activated or
memory CD81 T cells to divide (36). Later experiments
showed that this was probably due to the ability of IFN-a/b
to induce IL-15 production by cells such as macrophages
(15). We do not think that the IFN-a/b is acting in such a
way in the experiments described here. Experiments with
mixtures of wild-type and IFN-a/bR–deficient cells showed
that IFN-a/b were acting directly on the T cells and not in-
directly via induction of some other molecule. Also, as dis-
cussed above, apart from their common ability to prevent
the death of activated T cells, IFN-a/b and IL-15 affect T
cells in completely different ways.
The IFN-a/b were not as efficient in preventing the
deaths of activated T cells as the IL-2–related cytokines
were. This was not simply because the IL-2 family members
induced cell division and thus overgrowth of dead cells by
dividing T cells. Rather, at optimal concentrations IL-2 like
cytokines appeared to prevent activated T cell death almost
entirely, whereas the IFN-a/b simply slowed the process.
The IFN-a/b do not act via increased induction of an-
other survival protein, Bcl-X. Therefore, their effects are
probably not due to induction of members of the B7 family
and increased engagement of CD28 on T cells (19–24).
IFN-g did not share the ability of IFN-a/b to inhibit
the death of activated T cells. This was not because acti-
vated T cells lacked receptors for IFN-g, since IFN-g in-
creased class I MHC expression on such cells. Thus, the
rescuing activity of IFN-a/b must involve a feature of
signaling of the IFN-a/bR that is not shared with that of
the IFN-gR. There are several candidates for differential
factors. Although both receptors activate Stat1, only the
IFN-a/bR activates Stat2 and Stat4 and creates the hetero-
dimeric transcription factor, ISGF3 (38, 44–46). In addi-
tion, in T cells, the engaged IFN-a/bR is associated with
several proteins (p54lck, CD45, and Zap70) known to be
important in T cell activation (42). Perhaps one or more of
these properties of the IFN-a/bR distinguishes signaling
by IFN-a/b from that of IFN-g to T cells.
The fact that the IFN-a/b prevent activated T cell death
has considerable implications. It may contribute to the large
numbers of antigen-specific and nonspecific T cells that ap-
pear during virus infections (47–50). It may also account
for the long suspected association between virus infections
and induction of autoimmune diseases (51–53).
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